Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Eosinophilic Asthma Market Size, Value And Growth Trends Through 2030

The market for eosinophilic asthma experienced considerable expansion lately. Projections indicate a rise from $3.16 billion in 2025 to $3.71 billion in 2026, reflecting a compound annual growth rate of 17.4%. This upward trajectory is underpinned by factors observed throughout the historical period, including diminished responsiveness to inhaled corticosteroids, an increasing incidence of asthma, the successful identification of eosinophil biomarkers, a higher number of hospital admissions for asthma-related issues, and the overall impact of chronic respiratory diseases.

The market for eosinophilic asthma is poised for substantial expansion in the upcoming years, projected to reach $6.92 billion by 2030, driven by a compound annual growth rate of 16.9%. This anticipated surge is fueled by several key factors, including advancements in precise asthma treatment modalities, the broadening of biologic drug development pipelines, the increasing utilization of biomarker-driven diagnostic approaches, the growing emphasis on personalized respiratory care strategies, and the proliferation of specialized treatment centers. Furthermore, critical trends shaping this market over the forecast period encompass the accelerating embrace of biologic therapies, a heightened concentration on identifying and managing severe asthma phenotypes, escalating demand for immunotherapies specifically designed for targeted treatment, the continuous development of dedicated respiratory clinics, and a significant focus on mitigating the frequency of asthma exacerbations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

Eosinophilic Asthma Market Growth Factors Supporting Long-Term Expansion

An increase in smoking behaviors is anticipated to be a primary driver for the expansion of the eosinophilic asthma market. These behaviors encompass the consistent patterns of tobacco product consumption, including how often, under what circumstances, and for how long individuals smoke, frequently shaped by psychological, societal, and environmental influences. Escalating smoking rates can be attributed to various elements, such as heightened stress levels, strategic promotional efforts by tobacco corporations, insufficient knowledge regarding health hazards, and the cultural acceptance of smoking in specific communities. Treatments for eosinophilic asthma, which focus on mitigating airway inflammation and enhancing respiratory capacity, can provide an impetus for individuals to quit smoking by addressing the pulmonary difficulties that often perpetuate the habit. As an illustration, data from the Office for National Statistics in the UK indicated that in November 2025, the prevalence of e-cigarette use among women in Great Britain rose from 8.5% in 2023 to 10.0% in 2024. Moreover, the highest rates of daily e-cigarette use were observed in Great Britain among individuals aged 25 to 34 and 35 to 49 years, registering 9.3% and 9.5% respectively, with an upward trend noted for both demographics from 2023. Consequently, the growing incidence of smoking is a significant factor fueling the eosinophilic asthma market.

Eosinophilic Asthma Market Segment Landscape And Growth Potential

The eosinophilic asthma market covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

Eosinophilic Asthma Market Industry Trends Shaping Future Revenue Growth

Leading entities within the eosinophilic asthma marketplace are focused on creating novel therapeutics aimed at specific immunological pathways, thereby mitigating inflammation and enhancing patient results through tailored interventions. Monoclonal antibodies are essentially engineered proteins, designed to replicate the body’s natural defense mechanisms against illnesses caused by agents like viruses and bacteria; their creation involves combining an antibody-producing cell with a cancerous cell, facilitating the mass production of identical antibodies. Highlighting this trend, AstraZeneca plc, a pharmaceutical giant from the UK, reported in August 2024 that its drug, Fasenra, had secured approval from China’s National Medical Products Administration for managing severe eosinophilic asthma. This particular therapy is designated for individuals suffering from severe eosinophilic asthma, a condition distinguished by elevated eosinophil counts, which often exacerbates asthmatic symptoms and inflammation. As a monoclonal antibody, Fasenra works by targeting and reducing eosinophils via a distinct method, strengthening the body’s immune response by attaching to the IL-5 receptor on eosinophils, which consequently lowers their concentration in both the bloodstream and bodily tissues. The administration schedule includes an initial dose escalation period followed by ongoing maintenance treatments, typically involving injections administered every four weeks for the initial three doses, after which the interval extends to every eight weeks.

Eosinophilic Asthma Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

Access The Complete Eosinophilic Asthma Market Report:

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Eosinophilic Asthma Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the eosinophilic asthma market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model